Search Results

You are looking at 181 - 190 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

Letter to the Editor: Integrating Skeletal Muscle Mass and Radiodensity Improves Outcome Prediction and Correlation in Oncologic Studies

Grant R. Williams, Marc S. Weinberg, and Shlomit S. Shachar

dichotomizing participants as high or low radiodensity, why not integrate these 2 variables into 1 continuous variable? Because both muscle mass and radiodensity are defined independently and both are prognostic of many adverse cancer outcomes, we have proposed

Full access

CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients

Yunyun Liu, KKL Chan, and Hui Zhou

relapse, indicating that the poorer outcome of patients with NACT>3 may not be caused by chemo-induced resistance. The reason of worse outcomes after more cycles of NACT is still needed to be explored. CLO22-060 Figure 1 CLO22-060 Table 1

Full access

QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines

Kristen Burns, Archana Shenoy, and Nicole Turkoglu

population, examine policy and nursing practices to better navigate patients through the continuum of oncology care and improve patient outcomes. The purpose is to describe how the formation of an evidence-based practice committee can engage specialized

Full access

CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma

Karen Valdés-Díaz, Halbert Hernández-Negrín, Leonel Valdés-Leiva, Diana Martin-Oliva, and Dianelys Pedraza-González

Background: Comorbidity in elderly has made it difficult to manage when they are affected by aggressive non-Hodgkin's lymphoma. This has led to the historical achievement of poor outcomes, hence the analysis of the impact of comorbidity in this

Full access

HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia

Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai

decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a

Full access

Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and

Full access

CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer

Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem

in ongoing phase III clinical trials. This study aims to understand the prevalence, current treatment patterns and outcomes of HER2-low patients. Methods : This descriptive study analyzed data from a patient tumor registry in the Huntsman Cancer

Full access

Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone

Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann

BT + ADT Relative to EBRT Alone Given the significant potential selection bias for EBRT versus BT, IPTW was used to balance covariables that influenced both treatment allocation and outcomes, and weight-adjusted Cox regression was used to

Full access

HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer

Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo

) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1

Full access

HSR21-076: Valued Outcomes in the Cancer Experience (VOICE™): Developing and Validating a Measure of Patient Experience

Alexandra K. Zaleta, Erica E. Fortune, Melissa F. Miller, Branlyn W. DeRosa, Joanne S. Buzaglo, Karen Hurley, Mitch Golant, Sara Goldberger, Bruce Rapkin, Lillie D. Shockney, Jemeille Ackourey, and Kelly A. Clark

Background: Despite recognition that patient perspectives should inform cancer care, validated measures that meaningfully capture the patient experience across the cancer continuum remain lacking. We developed Valued Outcomes in the Cancer